Beclomethasone Dipropionate

證據等級: L5

預測適應症: 5 個

Beclomethasone Dipropionate: From Inhaled Corticosteroid Therapy to Asthma

One-Sentence Summary

Beclomethasone Dipropionate (BDP) is a synthetic inhaled corticosteroid (ICS) widely used for managing chronic airway inflammation. The TxGNN model predicts it may be effective for Asthma, with 50 clinical trials and 20 publications currently supporting this direction — making it one of the most extensively validated predictions in the dataset.

Quick Overview

Item	Content
Original Indication	(Approved indication text not available in current dataset; BDP is a well-established ICS for respiratory inflammatory conditions)
Predicted New Indication	Asthma
TxGNN Prediction Score	0.00% (rank 1)
Evidence Level	L1
Malaysia Market Status	✓ Marketed
Number of Registrations	27
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Beclomethasone Dipropionate is an inhaled glucocorticosteroid (ICS) that acts directly on airway epithelial cells and immune cells. Its active metabolite, beclomethasone-17-monopropionate (B17MP), binds to intracellular glucocorticoid receptors, suppressing the transcription of pro-inflammatory cytokines, reducing eosinophilic infiltration, decreasing mucus secretion, and attenuating bronchial hyperresponsiveness. This mechanism is squarely aligned with the Th2-mediated eosinophilic inflammation that characterises asthma.

BDP was in fact the first corticosteroid found to be clinically effective when delivered by aerosol inhalation, representing a landmark advance in asthma therapy since the early 1970s. The TxGNN prediction reflects an exceptionally strong mechanistic match: the drug’s anti-inflammatory action on the airway is the direct causal mechanism by which asthma symptoms are controlled. This prediction effectively serves as a positive validation of the model, as the drug–disease pairing is already well-established in clinical practice worldwide.

Furthermore, the evidence base spans over five decades of clinical research, including multiple large-scale Phase 3 randomised controlled trials, meta-analyses, and real-world effectiveness studies. BDP has been studied across diverse populations — from preschool children to elderly adults, from mild persistent to severe corticosteroid-dependent asthma — reinforcing the robustness of this drug–indication relationship.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00861926	Phase 3	Completed	2,079	48-week multinational RCT comparing Foster (BDP/formoterol) for maintenance and reliever vs fixed-dose maintenance plus salbutamol reliever in asthmatics ≥18 years
NCT02676089	Phase 3	Completed	1,433	52-week RCT comparing extrafine BDP/FF/GB triple therapy vs BDP/FF dual therapy ± tiotropium in uncontrolled asthma on high-dose ICS/LABA
NCT02676076	Phase 3	Completed	1,153	52-week RCT comparing extrafine BDP/FF/GB triple therapy vs BDP/FF dual therapy in uncontrolled asthma on medium-dose ICS/LABA
NCT01345916	Phase 3	Completed	932	8-week Phase 3 demonstrating CHF 1535 NEXT DPI non-inferior to pMDI and superior to BDP DPI alone in morning PEF
NCT00476268	Phase 3	Completed	824	24-week study evaluating efficacy and tolerability of BDP/formoterol in moderate to severe persistent asthma
NCT02513160	Phase 3	Completed	713	6-week RCT assessing BDP BAI at 320 or 640 mcg/day vs placebo in persistent asthma aged ≥12 years
NCT02040766	Phase 3	Completed	628	12-week RCT of BDP 80/160 mcg/day via BAI or MDI in pediatric patients aged 4–11 with persistent asthma
NCT03084718	Phase 2	Completed	610	8-week dose-ranging study of 3 doses of CHF 718 pMDI (HFA-BDP) to identify optimal dose in asthmatics
NCT00094016	Phase 3	Completed	440	12-week Phase 3 comparing QVAR Easi-Breathe 100 and 200 mcg/day vs placebo on FEV1 in asthmatic children
NCT01450774	Phase 3	Completed	72	Double-blind crossover comparing CHF1535 (BDP/formoterol) fixed combination vs free combination on safety (knemometry, urinary cortisol) in asthmatic children

Literature Evidence

PMID	Year	Type	Journal	Key Findings
9519232	1998	Meta-analysis	Respir Med	Meta-analysis of 14 trials: fluticasone at half the mcg dose of BDP or budesonide achieves equivalent clinical efficacy, with BDP serving as the standard comparator
6381025	1984	Systematic Review	Drugs	Decade-long reappraisal confirming BDP 400–800 mcg/day reduces oral steroid need in most asthma patients; doses up to 2000 mcg may add benefit in severe cases
8334070	1993	Comparative Study (RCT)	Br J Clin Pract	Consensus of multiple studies: BDP and budesonide are of equivalent therapeutic efficacy in asthma; B17MP active metabolite contributes to bronchial activity
10193530	1998	Comparative Study	Respir Med	Comparison of BDP and budesonide efficacy in asthma treatment, confirming comparable clinical outcomes
40219730	2025	Review	Ther Adv Respir Dis	Review of extrafine BDP/FF/G single-inhaler triple therapy (SITT) as add-on strategy for difficult-to-treat and severe asthma
36573485	2022	Review	Recent Prog Med	BDP as first ICS molecule (1970s); effective via nebulizers and pMDI in reducing asthma symptom frequency and severity with high safety profile
9657561	1998	RCT	Eur Respir J	Low-dose BDP (336 mcg/day) significantly improves asthma control and reduces airway inflammation markers vs placebo in mild–moderate asthma
3194866	1988	RCT	Thorax	Crossover study in chronic asthma: inhaled BDP 1200 mcg/day equivalent to oral prednisone 12.5 mg/day in reducing bronchial hyperresponsiveness
6792963	1981	Review	Ann Intern Med	5-year clinical experience confirming BDP as effective topical corticosteroid; most steroid-dependent asthmatics controllable; dose-dependent therapeutic effect
1095170	1975	Clinical Report	Can Med Assoc J	In 41 perennial asthma patients, 12/31 steroid-dependent patients discontinued oral prednisone; 15/31 reduced maintenance dose with BDP aerosol

Malaysia Market Information

Authorization Number	Product Name	Dosage Form	Approved Indication
(Details not available)	—	—	—
(Details not available)	—	—	—
(Details not available)	—	—	—
(Details not available)	—	—	—
(Details not available)	—	—	—

Note: A total of 27 registrations are recorded as marketed in Malaysia, but the detailed license information (authorization numbers, product names, dosage forms, approved indications) was not available in the current dataset. Please consult the NPRA database for full details.

Safety Considerations

Please refer to the package insert for safety information. Key warnings, contraindications, and drug interaction data were not available in the current evidence pack.

Additional Predicted Indications

Beyond the primary prediction, TxGNN also identified the following related indications for BDP:

Rank	Disease	Evidence Level	Clinical Trials	Publications	Recommendation
2	Allergic Asthma	L1	8	20	Proceed with Guardrails
3	Rhinitis	L1	23	20	Proceed with Guardrails
4	Intrinsic Asthma	L3	0	15	Proceed with Guardrails
5	Vasomotor Rhinitis	L3	0	15	Proceed with Guardrails

Key observations:

Allergic Asthma (Rank 2): BDP’s mechanism perfectly matches the Th2/IgE-mediated eosinophilic inflammation underlying allergic asthma. Multiple Phase 3 RCTs (e.g., NCT00988247, N=529) directly support this indication.
Rhinitis (Rank 3): BDP intranasal spray is already a first-line therapy for allergic rhinitis. Six completed Phase 3 trials with over 3,000 total subjects provide robust evidence.
Intrinsic Asthma (Rank 4): No registered clinical trials but 15 publications including direct clinical studies (PMID 1841740, PMID 329663) demonstrate efficacy of high-dose BDP in corticosteroid-dependent intrinsic asthma. The broader anti-inflammatory mechanism applies, though effect may be less consistent than in eosinophilic asthma.
Vasomotor Rhinitis (Rank 5): No registered clinical trials but controlled studies (PMID 782135, PMID 782136) from the 1970s demonstrate BDP significantly reduces symptoms of vasomotor rhinitis vs placebo. A 2009 systematic review (PMID 24228841) confirms intranasal corticosteroids’ role in VMR.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: BDP is one of the most extensively studied inhaled corticosteroids in the history of respiratory medicine. The TxGNN prediction for asthma aligns perfectly with over 50 years of clinical evidence, including dozens of completed Phase 3 RCTs with thousands of patients. All five predicted indications fall within the established pharmacological profile of this drug, effectively serving as a strong positive validation of the TxGNN model.

To proceed, the following is needed:

Complete the Malaysia NPRA registration details (27 licenses identified but specifics are missing)
Obtain detailed mechanism of action (MOA) data from DrugBank to formalise the mechanistic rationale
Retrieve package insert safety information (key warnings, contraindications, drug interactions) from the NPRA database
For intrinsic asthma and vasomotor rhinitis (L3 evidence), consider systematic literature review to consolidate existing evidence before formal repurposing pathway
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.